59721-29-8 | methanesulfonic acid 4-{2-[(dimethylcarbamoyl)methoxy]-2-oxoethyl}phenyl 4-carbamimidamidobenzoate

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$7.00	$5.00
10mg	95%	in stock	$12.00	$9.00
50mg	95%	in stock	$22.00	$16.00
100mg	95%	in stock	$34.00	$24.00
250mg	98%	in stock	$82.00	$58.00
1g	95%	in stock	$145.00	$102.00
5g	98%	in stock	$395.00	$277.00
10g	98%	in stock	$667.00	$467.00
25g	98%	in stock	$1,319.00	$923.00

Description

• Catalog Number: AG64164
• Chemical Name: methanesulfonic acid 4-{2-[(dimethylcarbamoyl)methoxy]-2-oxoethyl}phenyl 4-carbamimidamidobenzoate
• CAS Number: 59721-29-8
• Molecular Formula: C21H26N4O8S
• Molecular Weight: 494.5181
• MDL Number: MFCD00941410
• SMILES: CS(=O)(=O)O.CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)N=C(N)N)C

Computed Properties

• Complexity: 695
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 9

Literature

• Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

  Chest 20130701

• Effect of a serine protease inhibitor on the progression of chronic renal failure.

  American journal of physiology. Renal physiology 20121015

• In vivo contribution of serine proteases to the proteolytic activation of γENaC in aldosterone-infused rats.

  American journal of physiology. Renal physiology 20121001

• An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

  The Journal of clinical investigation 20120402

• Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.

  Clinical and experimental nephrology 20120201

• Duodenal myotomy blocks reduction of meal size and prolongation of intermeal interval by cholecystokinin.

  Physiology & behavior 20120201

• Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds.

  Journal of pharmaceutical sciences 20110801

• The short term satiety peptide cholecystokinin reduces meal size and prolongs intermeal interval.

  Peptides 20110601

• ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock.

  Innate immunity 20110201

• Regulator of calcineurin 1 controls growth plasticity of adult pancreas.

  Gastroenterology 20100801

• Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate.

  Acta dermato-venereologica 20100701

• Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.

  Journal of gastroenterology 20100301

• Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease.

  The Journal of pharmacology and experimental therapeutics 20090501

• Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations.

  Protein science : a publication of the Protein Society 20090501

• Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.

  Journal of hypertension 20090101

• Modelling of tumour--host coexistence In vitro in the presence of serine protease inhibitors.

  In vivo (Athens, Greece) 20090101

• Activation of submucosal but not myenteric plexus of the gastrointestinal tract accompanies reduction of food intake by camostat.

  Regulatory peptides 20081009

• CCK-induced pancreatic growth is not limited by mitogenic capacity in mice.

  American journal of physiology. Gastrointestinal and liver physiology 20080501

• The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.

  Life sciences 20070501

• Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.

  Journal of gastroenterology 20070401

• Induction of early response genes in trypsin inhibitor-induced pancreatic growth.

  American journal of physiology. Gastrointestinal and liver physiology 20070201

• The papilla of Vater just below the pylorus presenting as recurrent duodenal ulcer bleeding.

  Internal medicine (Tokyo, Japan) 20070101

• [Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20060701

• Activation of the mTOR signalling pathway is required for pancreatic growth in protease-inhibitor-fed mice.

  The Journal of physiology 20060615

• Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.

  International journal of pharmaceutics 20060511

• Calcineurin-dependent and calcineurin-independent signal transduction pathways activated as part of pancreatic growth.

  Pancreas 20060401

• Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?

  Journal of gastroenterology and hepatology 20060401

• Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.

  Journal of gastroenterology and hepatology 20050601

• Water and enzyme secretion are tightly coupled in pancreatic secretion stimulated by food or CCK-58 but not by CCK-8.

  American journal of physiology. Gastrointestinal and liver physiology 20050501

• Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.

  Metabolism: clinical and experimental 20050501

• Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.

  Pancreas 20050101

• Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).

  In vivo (Athens, Greece) 20050101

• Tumor protein p53-induced nuclear protein 1 (TP53INP1) in spontaneous chronic pancreatitis in the WBN/Kob rat: drug effects on its expression in the pancreas.

  JOP : Journal of the pancreas 20040701

• Calcineurin mediates pancreatic growth in protease inhibitor-treated mice.

  American journal of physiology. Gastrointestinal and liver physiology 20040501

• [Autoimmune pancreatitis].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040110

• Circulating ethanol does not stimulate pancreatic secretion in conscious rats.

  Pancreas 20031101

• CCK-58 is the only detectable endocrine form of cholecystokinin in rat.

  American journal of physiology. Gastrointestinal and liver physiology 20030801

• Morphological relationship between intercalated duct and pancreatic islet in streptozotocin and/or camostat mesilate administrations in the chicken.

  Anatomia, histologia, embryologia 20030401

• A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions.

  Clinical hemorheology and microcirculation 20030101

• Different effects of oral administration of synthetic trypsin inhibitor on the pancreas between cholecystokinin-A receptor gene knockout mice and wild type mice.

  Japanese journal of pharmacology 20020701

• Novel trial for the treatment of steroid dependency in minimal change disease: combined therapy of camostat mesilate and glycyrrhizin.

  Nephron 20020301

• Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock.

  Shock (Augusta, Ga.) 20020301

• [Thoracic aortic aneurysm with chronic disseminated intravascular coagulation treated successfully with orally administered camostat mesilate, warfarin and aspirin].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20020301

• Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.

  Gastroenterology 20010601

• Effects of synthetic serine protease inhibitors on proliferation and collagen synthesis of human pancreatic periacinar fibroblast-like cells.

  Pancreas 20010401

• Preparation and characterization of biodegradable or enteric-coated microspheres containing the protease inhibitor camostat.

  The Journal of pharmacy and pharmacology 20010201

• Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.

  Regulatory peptides 19990630

• New orally active serine protease inhibitors.

  Journal of medicinal chemistry 19950707